MADRID, (EUROPA PRESS) Researchers from the University of Southern California has identified molecular markers specígraphics that can’w help predict the tumor recurrence in patients with cáncer de colon in phase II and III. The discovery, which has made p&number;public during the meeting’n annual of the American Society of Oncología Clínica held these días in Chicago (united States), couldíto help identify patients that más benefits can be obtained from the chemotherapy, complementary to surgery, laser treatment’.
In the case of patients with cáncer de colon in phase III, in which the tumor has spread to the n’plugins linfáticos, it is recommended that additional chemotherapy to prevent recurrence of the tumor. In the case of stage II, surgery, laser treatment’is usually sufficient but in the 20 and 30 per cent of the patients the disease recurs and causes death. S&number;n explains Heinz-Josef Lenz, lead author of the study, "this is the first study that demonstrates that the genes of the mechanism of the angiogécluster biogenesis have a role in crítico in the recaída". Is called angiogécluster biogenesis formation’n of vessels sanguíneos that provide nutrients and oxígeno for the tumor to continue to grow. Lenz&bath;wing, these molecular markers not s’assistán to identify patients at higher risk, but that can’an be críticos to select the therapy más effective. The researchers analyzed samples sanguíneas obtained from facilities médicas between 1999 and 2007 to assess whether a possible patr’n specífico of polymorphisms in 33 genes involved in the progression’n the cáncer podíto predict recurrence of the tumor. Of the 197 patients who participated, 72 were in phase II and 123 in phase III of the cáncer de colon. The researchers identified the proteína of the vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 as one of the más important activators of the angiogécluster biogenesis of the tumor. The results showed that patients with polymorphisms in genes of EGFR and VEGFR tenían increased likelihood of recurrence of the disease. The results alsoén showed that patients with cáncer colorectal, phase II seems so feminine’an have a molecular profile that is different for the tumor recurrence. However, researchers&bathrooms;alan to beán required más studies to validate these preliminary data. The treatment with chemotherapy complementary for patients in phase II is controversial, as the largestíto them does not suffer recurrence, however the results of the study can’w help to identify the smaller percentage in which the disease is reproduced.